Weekly Analysts’ Ratings Changes for IGM Biosciences (IGMS)

Several analysts have recently updated their ratings and price targets for IGM Biosciences (NASDAQ: IGMS):

• 1/13/2025 – IGM Biosciences was upgraded by analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating.
• 1/10/2025 – IGM Biosciences was downgraded by analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating. They now have a $2.00 price target on the stock, down previously from $12.00.
• 1/10/2025 – IGM Biosciences was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $1.50 price target on the stock, down previously from $20.00.
• 1/10/2025 – IGM Biosciences had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $3.00 price target on the stock, down previously from $22.00.
• 1/10/2025 – IGM Biosciences was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating.
• 1/10/2025 – IGM Biosciences had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $2.00 price target on the stock, down previously from $21.00.
• 1/10/2025 – IGM Biosciences had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $2.00 price target on the stock, down previously from $48.00.
• 1/10/2025 – IGM Biosciences had its price target lowered by analysts at Truist Financial Co. from $12.00 to $2.00. They now have a “hold” rating on the stock.
• 1/10/2025 – IGM Biosciences was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $2.50 price target on the stock, down previously from $27.00.
• 12/6/2024 – IGM Biosciences is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $21.00 price target on the stock.

IGM Biosciences Price Performance

Shares of NASDAQ IGMS opened at $1.70 on Thursday. The firm’s 50-day moving average is $7.23 and its two-hundred day moving average is $10.72. The company has a market capitalization of $101.08 million, a PE ratio of -0.47 and a beta of 0.11. IGM Biosciences, Inc. has a 12-month low of $1.59 and a 12-month high of $22.50.

IGM Biosciences (NASDAQ:IGMS) last announced its earnings results on Friday, November 8th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.19). IGM Biosciences had a negative net margin of 7,534.03% and a negative return on equity of 155.42%. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.23 million. On average, analysts forecast that IGM Biosciences, Inc. will post -3.35 EPS for the current fiscal year.

Institutional Trading of IGM Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IGMS. Rhumbline Advisers grew its position in shares of IGM Biosciences by 13.1% in the second quarter. Rhumbline Advisers now owns 22,726 shares of the company’s stock valued at $156,000 after purchasing an additional 2,635 shares during the period. Bank of New York Mellon Corp grew its holdings in IGM Biosciences by 8.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 53,980 shares of the company’s stock valued at $371,000 after buying an additional 4,427 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of IGM Biosciences by 8.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 74,612 shares of the company’s stock valued at $1,234,000 after acquiring an additional 5,683 shares during the last quarter. Barclays PLC lifted its holdings in shares of IGM Biosciences by 48.4% during the 3rd quarter. Barclays PLC now owns 21,554 shares of the company’s stock worth $356,000 after acquiring an additional 7,027 shares during the period. Finally, XTX Topco Ltd lifted its holdings in shares of IGM Biosciences by 70.9% during the 2nd quarter. XTX Topco Ltd now owns 20,408 shares of the company’s stock worth $140,000 after acquiring an additional 8,467 shares during the period. Hedge funds and other institutional investors own 42.79% of the company’s stock.

IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.